New loan financing brings a warrant for up to 4M DocGo (DCGO) shares.
DocGo (DCGO) has amended and restated its credit agreement, securing an additional $12.5 million funded loan (Term Loan B) and another $12.5 million (Term Loan C) tied to a merger. As part of this financing, DocGo issued the administrative agent a fully vested warrant to purchase up to 4 million shares of common stock at an exercise price of $0.5039 per share. This warrant, exercisable through October 1, 2036, could lead to dilution for existing shareholders if exercised.
BTIG Maintains DocGo(DCGO.US) With Hold Rating
BTIG has reiterated its Hold rating for DocGo (DCGO.US). This indicates that the analyst firm is not recommending buying or selling the stock at this time, suggesting they view its current valuation as fair or believe there are no significant catalysts for a strong price movement in the near term.
Promising Penny Stocks To Consider In October 2026
This article highlights three promising penny stocks for October 2026: DocGo (DCGO), Motorsport Games (MSGM), and Blue Ridge Bankshares (BRBS). Each company is analyzed for its financial health, recent performance, and future outlook, with considerations for growth opportunities despite potential risks associated with penny stocks. The market has seen an 11% rise in the past year, with earnings expected to grow by 18% annually.
DocGo Price Target Maintained With a $3.00/Share by Needham
Needham has reiterated its Buy rating for DocGo (NASDAQ:DCGO) and maintained a price target of $3.00 per share. This suggests that Needham continues to see significant upside potential for the company's stock.
Needham reiterates Buy rating on DocGo, $3 price target
Needham has reiterated its Buy rating on DocGo (DCGO) with a $3.00 price target, suggesting a significant upside of 715.2% from its previous closing price. The positive outlook is attributed to DocGo's strategic acquisition of Hicuity Health's virtual care platform, which is expected to boost revenue and operational synergies. Additionally, the analyst notes strong financial management and a proactive debt repayment strategy, enhancing investor confidence.
DocGo (DCGO) Stock Analysis Report | Ratings, Financials & Performance
This report provides a comprehensive analysis of DocGo (DCGO) stock, covering its general information, financial health, and past performance. DocGo is a mobile health services provider with two segments: Mobile Health Services and Transportation Services. The analysis includes key financial indicators like operating margin, quick ratio, and debt-to-equity, along with a review of its 5-year Sharpe ratio.
DocGo Inc.(NasdaqCM: DCGO) dropped from S&P Global BMI Index
DocGo Inc. (NasdaqCM: DCGO) has been removed from the S&P Global BMI Index. This announcement follows several recent company activities, including presenting at a global healthcare conference, reporting Q2 2026 earnings where net loss widened and revenue fell, and acquiring Hicuity Health, Inc. The company also updated its earnings guidance and extended its equity buyback plan.
DocGo at Morgan Stanley healthcare conference: margin push takes center stage
DocGo presented its strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, aiming for adjusted EBITDA profitability by year-end through revenue optimization, margin improvement, and cost cuts. The company detailed plans to exit underperforming markets, automate back-office functions, and leverage its Hicuity Health acquisition to bridge hospital and home-based care. Despite recent stock performance challenges, DocGo emphasized its technology-enabled mobile health platform and commitment to improving outcomes to drive future growth and profitability.
DCGO | DocGo Inc. Common Stock Financials - Revenue Breakdown
This page provides a detailed financial overview of DocGo Inc. (DCGO), focusing on its revenue breakdown, though specific segment and geographic revenue data are noted as unavailable. It also includes sections on insider trading, institutional holdings, analyst ratings, and a company profile. The platform aims to offer comprehensive financial insights for investors.
Norton Rose Fulbright advises DocGo on acquisition of Hicuity Health
Norton Rose Fulbright advised DocGo Inc. on its acquisition of Hicuity Health, a virtual care provider, and related debt financing with Perceptive Advisors. The acquisition, valued at approximately US$52 million in assumed debt, is set to expand DocGo's virtual and in-home healthcare platform. Perceptive Advisors also committed an additional US$50 million in debt financing to support DocGo's growth.
DocGo Raises SteadyMD Earnout Liability To $5 Million From $2.3 Million As Telehealth Revenue Outlook Improves
DocGo has increased its estimated contingent consideration liability for the SteadyMD acquisition from $2.3 million to $5 million, reflecting a more optimistic revenue outlook for the telehealth business. This adjustment resulted in a $2.7 million fair-value loss in the first half but indicates an expected improvement in SteadyMD's performance. The stronger outlook for SteadyMD is crucial for DocGo as it faces declining revenues from migrant-related government programs, making growth from new businesses vital for future financial health and liquidity.
Top Penny Stocks To Watch In August 2026
This article identifies three penny stocks—DocGo (DCGO), NET Power (NPWR), and Liquidmetal Technologies (LQMT)—for investors to watch in August 2026. Despite facing challenges typical of smaller companies like unprofitability and high volatility, these companies exhibit strong financial health indicators such as low debt and sufficient cash runways. The article advises investors to look for robust financials and clear growth trajectories in this segment.
Canaccord Genuity Group Reaffirms "Hold" Rating for DocGo (NASDAQ:DCGO)
Canaccord Genuity Group has reiterated its "Hold" rating for DocGo (NASDAQ:DCGO), maintaining a $1.00 price target, which implies an 85.9% upside from its current share price of $0.54. Analyst sentiment for DocGo is mixed, with a consensus "Hold" rating and an average target price of $2.38 among six analysts. DocGo's shares recently dropped 24.2% to $0.54, while institutional investors hold 56.44% of the company's stock.
DocGo stock price target maintained at $2.50 by Stifel
Stifel maintained a Buy rating and $2.50 price target for DocGo (NASDAQ:DCGO) despite the company reporting Q2 revenue and EBITDA below consensus. DocGo is acquiring Hicuity Health, a virtual care provider, which Stifel believes could be synergistic and accelerate growth. The firm views 2026 as a transition year as DocGo aims for breakeven EBITDA by the end of 2026 and trades at 0.1 times revenue, reflecting current risk and reward.
Press Release: DocGo Announces Second Quarter 2026 Results
This press release from DocGo announces the company's financial results for the second quarter of 2026. Further details about these results would be contained within the full document of the press release.
DocGo (NASDAQ:DCGO) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC has reaffirmed its "buy" rating for DocGo (NASDAQ:DCGO) and set a price target of $3.00, suggesting a potential upside of 322.48% from its current price. Despite this, the stock has an overall "Hold" rating from analysts with an average price target of $2.38. DocGo is an integrated healthcare company providing on-demand and mobile healthcare services through customized medical clinics and a digital care platform.
DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast
DocGo (NASDAQ:DCGO) shares dropped significantly after the company reported weaker-than-expected second-quarter 2026 results and substantially increased its projected full-year adjusted EBITDA loss. The mobile healthcare provider's revenue was impacted by the wind-down of migrant-related contracts, and its profitability outlook worsened, leading to investor concern. The acquisition of Hicuity Health also adds integration risk while the company faces a negative market backdrop and Nasdaq listing compliance issues.
DocGo Releases Q2 2026 Financial Results
DocGo Inc. reported a wider-than-expected diluted loss of $0.16 per share for Q2 2026 and revenue of $73.4 million, falling short of analyst expectations. The company attributes the miss to its restructuring efforts away from migrant services, though core operations excluding migrant programs showed a 19% revenue climb. DocGo provided full-year revenue guidance between $305.0 million and $310.0 million, and analyst consensus remains cautiously balanced with 4 buys and 4 holds.
DocGo posts Q2 miss, cuts adjusted EBITDA outlook
DocGo (NASDAQ:DCGO) reported a Q2 earnings and revenue miss, delivering a loss of -$0.16 per share against an estimated -$0.10, and revenue of $73.4 million versus a $75.4 million consensus. The company also significantly lowered its full-year adjusted EBITDA outlook to -$17 million to -$22 million. Despite the financial miss and outlook cut, DocGo's shares were up 1% in after-hours trading, possibly due to the announcement of its definitive agreement to acquire virtual care provider Hicuity Health.
DocGo (NASDAQ: DCGO) warns on liquidity as losses widen
DocGo (NASDAQ: DCGO) reported a net loss of $34.69 million on revenues of $148.98 million for the first six months of 2026, widening from a $24.37 million net loss on $176.45 million in revenue during the same period in 2025. The company also indicated a going-concern risk due to ongoing operating losses and non-compliance with a minimum liquidity covenant under its credit agreement. DocGo is actively negotiating with its lender and exploring cost-reduction and cash-preservation strategies, including a potential replacement term loan and shifting compensation to stock, to address its liquidity issues.
Earnings call transcript: DocGo misses Q2 2026 estimates as stock falls after hours
DocGo reported Q2 2026 results that missed Wall Street expectations, with an adjusted loss per share of $0.16 and revenue of $73.4 million. The company's stock fell 11.28% after hours despite a regular-session gain, due to the earnings miss, a wider full-year loss outlook, and plans for a Hicuity Health acquisition. DocGo aims for positive adjusted EBITDA run rate by the end of 2026, driven by revenue growth, margin recovery, and cost efficiencies.
DocGo to acquire virtual care company Hicuity Health
DocGo has announced its agreement to acquire Hicuity Health, a virtual care company, by assuming its $52 million existing debt. This deal will make Hicuity a wholly-owned subsidiary of DocGo's Ambulnz Holdings. The Series F preferred shareholder of Hicuity will receive DocGo shares, with potential for more if DocGo's market capitalization reaches $250 million within three years.
DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates
DocGo Inc. (DCGO) reported Q2 earnings of $0.16 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.04 per share. Despite this earnings beat, the company's revenues of $73.43 million missed the consensus estimate and were lower than the previous year. The stock has underperformed the S&P 500 year-to-date, and its future performance will likely depend on management's commentary and evolving earnings expectations.
DocGo (NASDAQ:DCGO) Posts Earnings Results, Misses Estimates By $0.06 EPS
DocGo (NASDAQ:DCGO) announced its quarterly earnings, reporting a loss of $0.16 per share, missing analyst expectations by $0.06, and revenue of $73.42 million, below the $75.35 million consensus. Despite the earnings miss, the stock rose 6.4% to $0.71, with trading volume exceeding its daily average. Analysts hold a "Hold" rating on DocGo with an average target price of $2.38, and institutional investors own 56.44% of the company's shares.
DocGo (NASDAQ: DCGO) to buy Hicuity virtual care business and tap $50M in loans
DocGo (NASDAQ: DCGO) announced an agreement to acquire virtual care provider Hicuity Health through a stock-for-equity transaction and the assumption of Hicuity's debt, which is estimated to be approximately $52 million. Perceptive Advisors has committed up to an additional $50 million in new senior secured term loans for DocGo. This acquisition is expected to add approximately $65 million in trailing-12-month revenue and $4.5 million in adjusted EBITDA for Hicuity Health, expanding DocGo's offerings into high-acuity virtual clinical care.
DocGo Inc. 2026: Revenue $73.42M, EPS ($0.16) — 10-Q Summary
DocGo Inc. reported a Q2 2026 revenue of $73.42M and a diluted loss per share of ($0.16), showing a decline compared to the prior year. This decrease was primarily due to the wind-down of migrant-related Mobile Health contracts, though Transportation Services saw modest growth and the company implemented measures like headcount reduction and AI investment to manage costs and pursue new opportunities.
DocGo Announces Second Quarter 2026 Results
DocGo (Nasdaq: DCGO) announced its second-quarter 2026 financial results, revealing total revenue of $73.4 million, a decline from $80.4 million in Q2 2025 primarily due to the wind-down of migrant-related programs. Excluding these programs, revenue increased 19% year-over-year. The company also announced a definitive agreement to acquire virtual care provider Hicuity Health and new term loan funding from Perceptive Advisors, while narrowing its full-year 2026 revenue guidance to $305-$310 million and updating adjusted EBITDA expectations to ($17-$22) million.
DocGo agrees to acquire virtual care provider Hicuity Health, assumes $52M debt
DocGo announced its acquisition of virtual care provider Hicuity Health, including the assumption of approximately $52 million in Hicuity's debt. This move aims to expand DocGo's virtual care offerings, building on its previous acquisition of SteadyMD. The announcement coincided with DocGo's Q2 2026 earnings report, which showed a revenue decline due to the wind-down of migrant-related programs but strong growth in core business lines and record volumes.
Earnings To Watch: DocGo Inc (DCGO) Q2 2026 -- GF Value Sees 151% Upside
DocGo Inc (DCGO) is scheduled to release its Q2 2026 earnings on August 17, 2026, with revenue estimated at $75.4 million and an expected loss of $0.06 per share. Analysts have an average target price of $1.88, suggesting a 187.05% upside from the current price of $0.65, while GuruFocus estimates a 151.07% upside based on its GF Value. The company has an "Outperform" brokerage recommendation, despite past earnings missing expectations.
Press Release: DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo is scheduled to announce its second quarter 2026 financial results on Monday, August 17, 2026. The company will also host a conference call and webcast to discuss these results. Interested parties can access the webcast or dial in to participate.
DocGo to announce Q2 2026 results on Aug 17
DocGo Inc (NASDAQ: DCGO) is scheduled to release its second-quarter 2026 financial results after market close on Monday, August 17, 2026. The company will also host a conference call and webcast at 5:00 p.m. ET on the same day to discuss its quarterly performance. Investors can access the webcast and dial-in details through DocGo's investor relations website.
DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo Inc. (Nasdaq: DCGO) announced that it will release its financial results for the second quarter ended June 30, 2026, after the markets close on Monday, August 17, 2026. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss these results. The company, a provider of technology-enabled mobile health and medical transportation services, has provided details for accessing the call and webcast.
DocGo (DCGO) seeks 5-day SEC extension for delayed Q2 2026 10-Q filing
DocGo Inc. has filed an NT 10-Q notification with the SEC, indicating that its Quarterly Report on Form 10-Q for the period ended June 30, 2026, will be filed late. The company stated that additional time is needed to complete and review financial statements and disclosures, and anticipates filing the report within the five-day extension period allowed under Rule 12b-25. DocGo also confirmed that all other required periodic reports over the past 12 months have been filed and does not foresee any significant change in its results of operations compared to the prior fiscal year.
DocGo Stock (DCGO) Opinions on Recent Price Movement
Social media discussions indicate that DocGo stock (DCGO) has recently declined to around $0.65 due to broader selling and short-term holders exiting positions, reflecting cautious market sentiment. DocGo reported Q1 2026 revenues of $75.6M, a 21.33% decrease year-over-year, and saw varied hedge fund activity with major institutions reducing holdings while others increased. Analysts have issued "Overweight" ratings and a median price target of $2.75 for DCGO.
DocGo Inc. (NASDAQ:DCGO) Receives Consensus Rating of "Hold" from Analysts
DocGo Inc. (NASDAQ:DCGO) has received a consensus "Hold" rating from six analysts, with an average 12-month price target of $2.375, significantly higher than its recent share price of $0.62. The company exceeded revenue expectations for its latest quarter, reporting $75.55 million against an estimated $72.48 million, but missed on earnings per share, posting a loss of $0.12 compared to an estimated loss of $0.02. Institutional investors and hedge funds own 56.44% of DocGo's shares.
DocGo Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and encouraging investors who suffered losses exceeding $100,000 between November 8, 2022, and September 17, 2023, to contact them. The investigation follows allegations that DocGo made false or misleading statements regarding its executive hiring processes, the efficacy of its services, and its financial prospects, leading to significant stock price drops after revelations about its migrant relocation contract and CEO's falsified biography. Investors have until December 26, 2023, to seek the role of lead plaintiff in the federal securities class action lawsuit.
DocGo Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and reminds investors who suffered losses between November 8, 2022, and September 17, 2023, of the December 26, 2023, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that DocGo made false and misleading statements regarding its executive hiring, the efficacy of its services in the New York City migrant relocation contract, and the professional background of its former CEO, Anthony Capone, leading to significant stock price drops following negative reports and his resignation. Investors are encouraged to contact the firm to discuss their legal rights.
DocGo Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and reminds investors of the December 26, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that DocGo made false and misleading statements regarding its executive hiring processes, the efficacy of its mobile health services, and faced significant reputational and regulatory scrutiny. These issues led to a decline in DocGo's stock price following reports about its migrant relocation contract, an investigation by the New York Attorney General, rejection of the contract by the New York City Comptroller, and the resignation of its CEO due to falsified credentials.
DocGo Granted Nasdaq Extension to Regain Listing Compliance
DocGo (DCGO) has received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. Shareholders have already approved a potential reverse stock split at a ratio between 1-for-5 and 1-for-10 to help achieve this. TipRanks' AI Analyst, Spark, rates DCGO as Neutral, citing deteriorating profitability and cash flow, despite some positive factors like raised revenue guidance and corporate actions.
DocGo Number of Employees 2026 | Employee Count & Headcount Data
DocGo, Inc. (NASDAQ: DCGO) has approximately 3,548 total employees worldwide as of March 2026, a 16.7% decline from 2023. The company is actively hiring, with 271 active job postings in 2026, and its workforce is primarily concentrated in the United States, followed by the United Kingdom and the Philippines. The average employee salary at DocGo is $63,167, with overall employee sentiment being negative and declining.
DocGo Granted Nasdaq Extension to Regain Listing Compliance
DocGo (DCGO) has received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. Shareholders have already approved a reverse stock split option to help the company meet this threshold. Analysts currently rate DCGO as a "Buy" with a $2.50 price target, though TipRanks' AI Analyst, Spark, notes concerns about profitability and cash flow.
DocGo | ARS: Annual Report to Security Holders
This document is an Annual Report to Security Holders (ARS) for DocGo. It indicates that the report is available for review, and includes a link to access the full SEC filing for detailed financial and operational information.
DocGo Shareholder Action Reminder
Faruqi & Faruqi, LLP reminds investors who suffered losses exceeding $50,000 in DocGo securities between November 8, 2022, and September 17, 2023, to contact the firm regarding a federal securities class action lawsuit. The lawsuit alleges that DocGo made false and misleading statements concerning executive hiring processes, the efficacy of its services for a $432 million migrant relocation contract, and faced significant reputational scrutiny due to issues with the contract and its former CEO's falsified biography. Investors have until December 26, 2023, to seek the role of lead plaintiff.
DocGo Disclosed Failure to Satisfy a Continued Listing Rule or Standard
DocGo (DCGO) received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company needs its stock to close at or above $1.00 for at least 10 consecutive business days, and a reverse stock split is a potential option authorized by shareholders. This information is based on an SEC filing from July 31, 2026.
DocGo Inc (DCGO) Financial Health: Profitability & Balance Sheet Analysis
DocGo Inc (DCGO) currently holds a financial score of 7.25, placing it 42nd out of 75 in the Healthcare Providers & Services industry, indicating a stable financial status and high operating efficiency. Despite this, the company experienced a 21.33% year-over-year decrease in its latest quarterly revenue to $75.55 million and a 56.97% decrease in net profit. Key financial metrics related to cash and cash equivalents, total assets, liabilities, free cash flow, quality of earnings, operational efficiency, growth potential, and shareholder returns are noted, though some relevant data have not been disclosed by the company.
DocGo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and encouraging investors who lost over $100,000 between November 8, 2022, and September 17, 2023, to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that DocGo made false or misleading statements regarding executive hiring, the efficacy of its services, and the negative impact of reputational and regulatory scrutiny. These issues, including problems with a $432 million migrant relocation contract and the CEO's falsified biography, led to significant drops in DocGo's stock price.
BlackRock (DCGO holder) discloses 1.4% DocGo Inc. stake in updated ownership
BlackRock, Inc. has filed an updated ownership report for DocGo Inc. (DCGO), disclosing a beneficial ownership of 1,361,645 shares, which represents 1.4% of the company's outstanding common stock. BlackRock holds sole voting and dispositive power over these shares, and no single underlying client holds more than a 5% interest in DocGo. The filing is a SCHEDULE 13G/A, indicating a passive investment.
DocGo Inc. Revenue Breakdown – NASDAQ:DCGO
DocGo Inc. (NASDAQ: DCGO) generated $322.20 million in revenue last year, with its Transportation Services segment being the top performer at $200.77 million. The majority of the company's revenue, $268.25 million, came from the United States.
DCGO|DocGo Inc|Price:0.641|Chg%:+0.045
This article provides a comprehensive stock analysis of DocGo Inc (DCGO), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status. It notes high institutional ownership and recent analyst ratings of "Buy" with a target price suggesting significant upside. The analysis also covers the company's business model, key strengths, and risks.
DocGo Inc (DCGO) Institutional Confidence
DocGo Inc (DCGO) has an institutional shareholding score of 3.00, placing it 55th out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 43.34%, a decrease of 45.16% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.53% of outstanding shares.
